One possible explanation for these findings is that because patients who were exposed to G-CSF appeared less likely to experience progression of lymphoma, they were exposed to other competing causes of death for longer than patients who did not receive G-CSF but with the proportional rate of non-lymphoma-related mortality being the same in both groups. The gene discussed is CSF3; the disease is lymphoma.